Johnson & Johnson Gross Profit 2006-2018 | JNJ

Johnson & Johnson annual/quarterly gross profit history and growth rate from 2006 to 2018. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Johnson & Johnson gross profit for the quarter ending September 30, 2018 was $13.759B, a 8.13% increase year-over-year.
  • Johnson & Johnson gross profit for the twelve months ending September 30, 2018 was $54.078B, a 6.77% increase year-over-year.
  • Johnson & Johnson annual gross profit for 2017 was $51.096B, a 1.77% increase from 2016.
  • Johnson & Johnson annual gross profit for 2016 was $50.205B, a 3.43% increase from 2015.
  • Johnson & Johnson annual gross profit for 2015 was $48.538B, a 5.91% decline from 2014.
Johnson & Johnson Annual Gross Profit
(Millions of US $)
2017 $51,096
2016 $50,205
2015 $48,538
2014 $51,585
2013 $48,970
2012 $45,566
2011 $44,670
2010 $42,795
2009 $43,450
2008 $45,236
2007 $43,344
2006 $38,267
2005 $36,504
Johnson & Johnson Quarterly Gross Profit
(Millions of US $)
Q3 2018 $13,759
Q2 2018 $13,903
Q1 2018 $13,395
Q4 2017 $13,021
Q3 2017 $12,725
Q2 2017 $12,993
Q1 2017 $12,357
Q4 2016 $12,572
Q3 2016 $12,334
Q2 2016 $13,146
Q1 2016 $12,153
Q4 2015 $12,138
Q3 2015 $11,878
Q2 2015 $12,430
Q1 2015 $12,092
Q4 2014 $12,401
Q3 2014 $13,068
Q2 2014 $13,456
Q1 2014 $12,660
Q4 2013 $12,400
Q3 2013 $12,231
Q2 2013 $12,388
Q1 2013 $11,951
Q4 2012 $11,555
Q3 2012 $11,455
Q2 2012 $11,332
Q1 2012 $11,224
Q4 2011 $10,917
Q3 2011 $10,933
Q2 2011 $11,425
Q1 2011 $11,395
Q4 2010 $10,604
Q3 2010 $10,388
Q2 2010 $10,700
Q1 2010 $11,103
Q4 2009 $11,239
Q3 2009 $10,647
Q2 2009 $10,789
Q1 2009 $10,775
Q4 2008 $10,810
Q3 2008 $11,147
Q2 2008 $11,699
Q1 2008 $11,580
Q4 2007 $11,223
Q3 2007 $10,696
Q2 2007 $10,773
Q1 2007 $10,652
Q4 2006 $9,675
Q3 2006 $9,637
Q2 2006 $9,575
Q1 2006 $9,380
Q4 2005 $8,972
Q3 2005 $8,956
Q2 2005 $9,240
Q1 2005 $9,336
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $391.677B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $259.009B 14.60
Merck (MRK) United States $205.072B 17.77
Novartis AG (NVS) Switzerland $203.357B 17.38
AbbVie (ABBV) United States $137.681B 12.22
Eli Lilly (LLY) United States $120.583B 21.20
Sanofi (SNY) France $113.115B 14.01
Novo Nordisk (NVO) Denmark $107.931B 17.53
AstraZeneca (AZN) United Kingdom $103.013B 12.79
GlaxoSmithKline (GSK) United Kingdom $100.041B 13.45
Bristol-Myers Squibb (BMY) United States $88.253B 14.53